Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN JAMES BUDD

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1669425989
CMS profile
211520
Location
SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,764.37

272 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,764.37 272

By paying entity

PY2019 · entire year · sorted by reported total

Page 6 of 6; records 251–272 of 272 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN JAMES BUDD

NPI 1669425989 · CMS profile ID 211520

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–272 of 272 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669425989?year=2019&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN JAMES BUDD, NPI 1669425989, CMS profile ID 211520. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–272 of 272 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669425989?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOHN JAMES BUDD, NPI 1669425989, CMS profile ID 211520. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–272 of 272 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669425989?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOHN JAMES BUDD, NPI 1669425989, CMS profile ID 211520, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–272 of 272 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1669425989?year=2019&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

272 matching records · $3,764.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 272 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–272 of 272.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $16.8502/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662530411 CMS
Janssen Biotech, Inc. $18.1301/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658350729 CMS
PFIZER INC. $14.6601/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672474239 CMS
UCB, Inc. $17.6301/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688254503 CMS
Antares Pharma, Inc. $16.8601/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676452125 CMS
E.R. Squibb & Sons, L.L.C. $12.6601/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651262705 CMS
Novartis Pharmaceuticals Corporation $22.3201/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658989307 CMS
AbbVie, Inc. $18.2801/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647880925 CMS
E.R. Squibb & Sons, L.L.C. $9.9801/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651262715 CMS
E.R. Squibb & Sons, L.L.C. $13.3101/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651262707 CMS
GlaxoSmithKline, LLC. $14.0801/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670541867 CMS
PFIZER INC. $11.5601/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672483789 CMS
GENZYME CORPORATION $23.7001/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693892621 CMS
AbbVie, Inc. $15.0301/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647880923 CMS
PFIZER INC. $3.3901/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672486571 CMS
UCB, Inc. $14.5401/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688246773 CMS
Genentech USA, Inc. $19.0301/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681291295 CMS
Janssen Biotech, Inc. $9.3801/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658350725 CMS
Amgen Inc. $12.1201/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662530415 CMS
PFIZER INC. $2.8101/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672429015 CMS
PFIZER INC. $3.0401/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672475851 CMS
GlaxoSmithKline, LLC. $11.7501/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670585217 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,764.37 272
PY2020 $2,948.87 204
PY2021 $3,361.55 249
PY2022 $3,514.91 212
PY2023 $2,954.34 167

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $43,630.05 27
PY2023 Principal investigator $35,396.00 20
PY2022 Principal investigator $16,313.21 19
PY2021 Principal investigator $33,585.74 21
PY2020 Recipient $160.60 2
PY2020 Principal investigator $122,921.47 44
PY2019 Recipient $1,485.95 11
PY2019 Principal investigator $136,095.76 44

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,096.17 11/01/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791551
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $505.70 09/23/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791549
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,738.15 09/20/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791545
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,771.73 09/20/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791547
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,426.58 09/11/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791543
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9.55 08/30/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791577
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $151.15 08/30/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791579
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $192.60 08/30/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791581
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $115.56 08/30/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791583
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $30.23 08/21/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791573
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $38.52 08/21/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791575
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,882.88 06/17/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791541
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,766.58 05/10/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791539
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $38.25 05/03/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791563
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $30.23 05/03/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791565
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $269.64 05/03/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791567
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $77.04 05/03/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791569
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $30.23 05/03/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791571
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,719.78 03/26/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791531
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $11,675.30 03/26/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791533
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $500.00 03/26/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791535
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $952.00 03/26/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791537
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $37.70 03/05/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791555
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $315.38 03/05/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791557
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $154.08 03/05/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791559
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $211.61 03/05/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791561
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,893.41 01/24/2024 Non-covered Recipient Entity
Clayton Medical Associates, PC dba Saint Louis Rheumatology
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1151791529